Nervous System Diseases

Symptoms and General Pathology

All Conditions

Neuralgia

Pain

Peripheral Nervous System Diseases

Neuromuscular Diseases

Neurologic Manifestations

Analgesics

Central Nervous System Depressants

All Drugs and Chemicals

Channel Blockers

Anticonvulsants

Psychotropic Drugs

Bone Density Conservation Agents

Oxycodone

Pregabalin

Calcium

Calcium Channel Blockers

Calcium, Dietary

Hormones

Anti-Anxiety Agents

Analgesics, Opioid

Narcotics

oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops

pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops

Arm A - 20 mg/day

Arm B - increasing dose startnig at 20 mg/day

For 15 days or until unacceptable toxicity develops.

oxycodone

Arm A - pregabalin at increasing dose starting from 50 mg/day

Arm B - pregabalin 50 mg/day

For 15 days or until unacceptable toxicity develops.

pregabalin

Gabriella Farina, MD

The aim of the study is to assess tolerability and activity of oxycodone and pregabalin in combination for the treatment of oncological neuropathic pain with two different strategies.

Neuropathic pain is frequently diagnosed as a complication of cancer pain. While opioids are the mainstay of cancer pain management,their efficacy in neuropathic pain seems to be less then optimal,and adjuvant drugs, mainly anticonvulsants and antidepressants,are often combined with opioids in the analgesic regimen of patients with neuropathic cancer pain. This approach is suggested by well-established guidelines, but the analgesic benefit and the safety of pregabalin and oxycodone in combination is not yet documented.

The aim of this study is to assess the activity and tolerability of the addition of pregabalin to oxycodone in the treatment of patients with neuropathic pain due to neoplasm.

Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain

Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain

Mario Negri Institute for Pharmacological Research

Associazione Progetto Oncologia UMAN.A

Gabriella Farina

Spots Global Cancer Trial Database for patients with cancer and presenting a neuropathic pain